Blame game slows growth of personalized medicine

its fat profits in the past. For example Erbitux, a cancer drug sold by Merck KGaA (MRCG.DE), Eli Lilly (LLY.N) and Bristol-Myers Squibb (BMY.N), has a smaller market because only around 65 percent of patients have the right gene type to allow the drug...